Dr. Geoff Oxnard is Vice President, Global Medical Lead, Liquid Portfolio at Foundation Medicine, where he advances the development of innovative studies demonstrating the clinical utility of the Liquid Franchise products.
Prior to joining Foundation Medicine, Dr. Oxnard was a thoracic oncologist at the Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. He graduated with honors from the University of Chicago School of Medicine, received his medical training at Massachusetts General Hospital, and performed an oncology fellowship at Memorial Sloan-Kettering Cancer Center. He was a clinic-based translational investigator whose research included studies of targeted therapies for genotype-defined NSCLC populations, noninvasive plasma genotyping technologies, and familial lung cancer due to germline EGFR mutations. He received grant funding from the National Cancer Institute, the Damon Runyon Cancer Research Foundation, the Conquer Cancer Foundation of ASCO, and the US Department of Defense. He has given oral presentations on his research at the Annual Meeting of the American Society of Clinical Oncology, the Annual Meeting of the American Association for Cancer Research, and the World Conference on Lung Cancer.
Updated: November 2020